Literature DB >> 18958182

Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases.

Hiroyuki Kobori1, Naro Ohashi, Akemi Katsurada, Kayoko Miyata, Ryousuke Satou, Toshie Saito, Tatsuo Yamamoto.   

Abstract

We previously reported that urinary excretion rates of angiotensinogen (AGT) provide a specific index of the activity of the intrarenal renin-angiotensin system in angiotensin II-dependent hypertensive rats. Meanwhile, we have recently developed direct enzyme-linked immunosorbent assays (ELISAs) to measure plasma and urinary AGT in humans. This study was performed to test a hypothesis that urinary AGT levels are enhanced in chronic kidney disease (CKD) patients and correlated with some clinical parameters. Eighty patients with CKD (37 women and 43 men, from 18 to 94 years old) and seven healthy volunteers (two women and five men, from 27 to 43 years old) were included. Plasma AGT levels showed a normal distribution; however, urinary AGT-creatinine ratios (UAGT/UCre) deviated from the normal distribution. When a logarithmic transformation was executed, Log(UAGT/UCre) levels showed a normal distribution. Therefore, Log(UAGT/UCre) levels were used for further analyses. Log(UAGT/UCre) levels were not correlated with age, gender, height, body weight, body mass index, systolic blood pressure, diastolic blood pressure, serum sodium levels, serum potassium levels, urinary sodium-creatinine ratios, plasma renin activity, or plasma AGT levels. However, Log(UAGT/UCre) levels were significantly correlated positively with urinary albumin-creatinine ratios, fractional excretion of sodium, urinary protein-creatinine ratios, and serum creatinine, and correlated negatively with estimated glomerular filtration rate. Log(UAGT/UCre) levels were significantly increased in CKD patients compared with control subjects (1.8801 +/- 0.0885 vs. 0.9417 +/- 0.1048; P = .0024). These data confirmed our earlier report and showed that a new ELISA assay is a valid approach for measuring urinary AGT.

Entities:  

Keywords:  Blood pressure; ELISA; plasma; renin-angiotensin system

Year:  2008        PMID: 18958182      PMCID: PMC2574500          DOI: 10.1016/j.jash.2008.04.008

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  35 in total

1.  Elements of a paracrine tubular renin-angiotensin system along the entire nephron.

Authors:  A Rohrwasser; T Morgan; H F Dillon; L Zhao; C W Callaway; E Hillas; S Zhang; T Cheng; T Inagami; K Ward; D A Terreros; J M Lalouel
Journal:  Hypertension       Date:  1999-12       Impact factor: 10.190

2.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

3.  Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension.

Authors:  H Kobori; L M Harrison-Bernard; L G Navar
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

4.  Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats.

Authors:  G Mazzocchi; L K Malendowicz; A Markowska; G Albertin; G G Nussdorfer
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-06       Impact factor: 4.310

5.  Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production.

Authors:  Hiroyuki Kobori; Lisa M Harrison-Bernard; L Gabriel Navar
Journal:  Kidney Int       Date:  2002-02       Impact factor: 10.612

Review 6.  Regulation of intrarenal angiotensin II in hypertension.

Authors:  L Gabriel Navar; Lisa M Harrison-Bernard; Akira Nishiyama; Hiroyuki Kobori
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

7.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

8.  Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension.

Authors:  Hiroyuki Kobori; Lisa M Harrison-Bernard; L Gabriel Navar
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

9.  Effects of dietary sodium and genetic background on angiotensinogen and Renin in mouse.

Authors:  Pierre Lantelme; Andreas Rohrwasser; Barbu Gociman; Elaine Hillas; Tong Cheng; Gray Petty; Jennifer Thomas; Sha Xiao; Tomoaki Ishigami; Tracy Herrmann; Daniel A Terreros; Kenneth Ward; Jean-Marc Lalouel
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

Review 10.  The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

Authors:  Hiroyuki Kobori; Masaomi Nangaku; L Gabriel Navar; Akira Nishiyama
Journal:  Pharmacol Rev       Date:  2007-09       Impact factor: 25.468

View more
  58 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 2.  Intratubular renin-angiotensin system in hypertension.

Authors:  L Gabriel Navar; Hiroyuki Kobori; Minolfa C Prieto; Romer A Gonzalez-Villalobos
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

3.  Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy.

Authors:  Yoshio Konishi; Akira Nishiyama; Takashi Morikawa; Chizuko Kitabayashi; Mikiko Shibata; Masahiro Hamada; Masatsugu Kishida; Hirofumi Hitomi; Hideyasu Kiyomoto; Takenori Miyashita; Nozomu Mori; Maki Urushihara; Hiroyuki Kobori; Masahito Imanishi
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

4.  Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes.

Authors:  Toshie Saito; Maki Urushihara; Yumiko Kotani; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Med Sci       Date:  2009-12       Impact factor: 2.378

Review 5.  Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Authors:  Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

Review 6.  Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications.

Authors:  Joseph L Alge; John M Arthur
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

7.  Urine angiotensinogen and salt-sensitivity and potassium-sensitivity of blood pressure.

Authors:  Casey M Rebholz; Jing Chen; Qi Zhao; Ji-Chun Chen; Jianxin Li; Jie Cao; Luis Gabriel Navar; Lotuce Lee Hamm; Dongfeng Gu; Jiang He
Journal:  J Hypertens       Date:  2015-07       Impact factor: 4.844

8.  Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients.

Authors:  Hiroyuki Kobori; A Brent Alper; Rajesh Shenava; Akemi Katsurada; Toshie Saito; Naro Ohashi; Maki Urushihara; Kayoko Miyata; Ryousuke Satou; L Lee Hamm; L Gabriel Navar
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

9.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

10.  Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy.

Authors:  Susumu Ogawa; Hiroyuki Kobori; Naro Ohashi; Maki Urushihara; Akira Nishiyama; Takefumi Mori; Tsuneo Ishizuka; Kazuhiro Nako; Sadayoshi Ito
Journal:  Biomark Insights       Date:  2009-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.